论文部分内容阅读
目的了解我院非瓣膜性房颤住院患者华法林临床应用情况,总结临床用药经验,为临床用药提供参考,探讨开展华法林临床药学监护的意义。方法查阅2012年1月至2014年12月我院第一心血管内科非瓣膜性房颤患者726例,并对抗凝方案的种类、华法林用药剂量、国际标准化比值(INR)监测等进行系统的回顾性调查分析。结果我院房颤患者常用抗凝方案包括双联抗血小板治疗、阿司匹林抗栓治疗和华法林等抗凝治疗。初始国际标准化比值(INR)为2.0~3.0的病例占13.8%,调整剂量后有43.4%的患者国际标准化比值(INR)达标。结论目前华法林的临床应用仍存在不足,继续提高人们对华法林的认知度和房颤的抗凝意识、积极开展华法林临床药学监护具有重要意义。
Objective To understand the clinical application of warfarin in hospitalized patients with nonvalvular atrial fibrillation (AF) and to summarize the experience of clinical medication, so as to provide reference for clinical medication and to explore the significance of warfarin clinical pharmacy monitoring. Methods A total of 726 patients with non-valvular atrial fibrillation in our hospital from January 2012 to December 2014 were enrolled in this study. The types of anticoagulation regimen, warfarin dosage and INR (International Normalized Ratio) Systematic review of the survey. Results Atrial fibrillation commonly used in our hospital anticoagulant programs include dual antiplatelet therapy, aspirin antithrombotic therapy and warfarin and other anticoagulant therapy. The initial INR (international standardization ratio) of 2.0 to 3.0 accounted for 13.8% of the patients, and 43.4% of the patients after adjustment of the dose reached the international standardization ratio (INR). Conclusion At present, the clinical application of warfarin is still inadequate. It is of great significance to continue to raise awareness of warfarin and anticoagulation awareness of atrial fibrillation, and actively carry out warfarin clinical pharmacy monitoring.